365 related articles for article (PubMed ID: 32376258)
21. Unravelling the dorsal periaqueductal grey matter NMDA receptors relevance in the nitric oxide-mediated panic‑like behaviour and defensive antinociception organised by the anterior hypothalamus of male mice.
Falconi-Sobrinho LL; Dos Anjos-Garcia T; Hernandes PM; Rodrigues BMP; Almada RC; Coimbra NC
Psychopharmacology (Berl); 2023 Feb; 240(2):319-335. PubMed ID: 36648509
[TBL] [Abstract][Full Text] [Related]
22. Postnatal maturation of endogenous opioid systems within the periaqueductal grey and spinal dorsal horn of the rat.
Kwok CHT; Devonshire IM; Bennett AJ; Hathway GJ
Pain; 2014 Jan; 155(1):168-178. PubMed ID: 24076162
[TBL] [Abstract][Full Text] [Related]
23. Microinjection of 2-arachidonoyl glycerol into the rat ventral hippocampus differentially modulates contextually induced fear, depending on a persistent pain state.
Rea K; Ford GK; Olango WM; Harhen B; Roche M; Finn DP
Eur J Neurosci; 2014 Feb; 39(3):435-43. PubMed ID: 24494683
[TBL] [Abstract][Full Text] [Related]
24. Role of glutamate NMDA receptors and nitric oxide located within the periaqueductal gray on defensive behaviors in mice confronted by predator.
Carvalho-Netto EF; Gomes KS; Amaral VC; Nunes-de-Souza RL
Psychopharmacology (Berl); 2009 Jul; 204(4):617-25. PubMed ID: 19241059
[TBL] [Abstract][Full Text] [Related]
25. Anti-aversive role of the endocannabinoid system in the periaqueductal gray stimulation model of panic attacks in rats.
Viana TG; Hott SC; Resstel LB; Aguiar DC; Moreira FA
Psychopharmacology (Berl); 2015 May; 232(9):1545-53. PubMed ID: 25388290
[TBL] [Abstract][Full Text] [Related]
26. Cannabidiol-induced panicolytic-like effects and fear-induced antinociception impairment: the role of the CB
Khan AU; Falconi-Sobrinho LL; Dos Anjos-Garcia T; de Fátima Dos Santos Sampaio M; de Souza Crippa JA; Menescal-de-Oliveira L; Coimbra NC
Psychopharmacology (Berl); 2020 Apr; 237(4):1063-1079. PubMed ID: 31919563
[TBL] [Abstract][Full Text] [Related]
27. Conditioned antinociception and freezing using electrical stimulation of the dorsal periaqueductal gray or inferior colliculus as unconditioned stimulus are differentially regulated by 5-HT2A receptors in rats.
Castilho VM; Brandão ML
Psychopharmacology (Berl); 2001 May; 155(2):154-62. PubMed ID: 11401004
[TBL] [Abstract][Full Text] [Related]
28. Interplay between 5-HT
Baptista-de-Souza D; Pelarin V; Canto-de-Souza L; Nunes-de-Souza RL; Canto-de-Souza A
Neuropharmacology; 2018 Sep; 140():100-106. PubMed ID: 30056125
[TBL] [Abstract][Full Text] [Related]
29. Blockade of mu- and activation of kappa-opioid receptors in the dorsal periaqueductal gray matter produce defensive behavior in rats tested in the elevated plus-maze.
Nobre MJ; Ribeiro dos Santos N; Aguiar MS; Brandão ML
Eur J Pharmacol; 2000 Sep; 404(1-2):145-51. PubMed ID: 10980273
[TBL] [Abstract][Full Text] [Related]
30. Attenuation of morphine antinociceptive tolerance by cannabinoid CB1 and CB2 receptor antagonists.
Altun A; Yildirim K; Ozdemir E; Bagcivan I; Gursoy S; Durmus N
J Physiol Sci; 2015 Sep; 65(5):407-15. PubMed ID: 25894754
[TBL] [Abstract][Full Text] [Related]
31. Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception.
Palazzo E; Marabese I; de Novellis V; Oliva P; Rossi F; Berrino L; Rossi F; Maione S
Neuropharmacology; 2001 Mar; 40(3):319-26. PubMed ID: 11166324
[TBL] [Abstract][Full Text] [Related]
32. Cannabinoid modulation of predator fear: involvement of the dorsolateral periaqueductal gray.
Lisboa SF; Camargo LH; Magesto AC; Resstel LB; Guimarães FS
Int J Neuropsychopharmacol; 2014 Aug; 17(8):1193-206. PubMed ID: 24438603
[TBL] [Abstract][Full Text] [Related]
33. Glutamatergic mechanisms of the dorsal periaqueductal gray matter modulate the expression of conditioned freezing and fear-potentiated startle.
Reimer AE; de Oliveira AR; Brandão ML
Neuroscience; 2012 Sep; 219():72-81. PubMed ID: 22698693
[TBL] [Abstract][Full Text] [Related]
34. A Tyr-W-MIF-1 analog containing D-Pro2 discriminates among antinociception in mice mediated by different classes of mu-opioid receptors.
Nakayama D; Watanabe C; Watanabe H; Mizoguchi H; Sakurada T; Sakurada S
Eur J Pharmacol; 2007 Jun; 563(1-3):109-16. PubMed ID: 17343845
[TBL] [Abstract][Full Text] [Related]
35. Cooperative regulation of anxiety and panic-related defensive behaviors in the rat periaqueductal grey matter by 5-HT1A and μ-receptors.
Roncon CM; Biesdorf C; Coimbra NC; Audi EA; Zangrossi H; Graeff FG
J Psychopharmacol; 2013 Dec; 27(12):1141-8. PubMed ID: 23598399
[TBL] [Abstract][Full Text] [Related]
36. Place aversion induced by blockade of mu or activation of kappa opioid receptors in the dorsal periaqueductal gray matter.
Sante AB; Nobre MJ; Brandão ML
Behav Pharmacol; 2000 Nov; 11(7-8):583-9. PubMed ID: 11198129
[TBL] [Abstract][Full Text] [Related]
37. Central antinociception induced by mu-opioid receptor agonist morphine, but not delta- or kappa-, is mediated by cannabinoid CB1 receptor.
Pacheco Dda F; Klein A; Perez AC; Pacheco CM; de Francischi JN; Reis GM; Duarte ID
Br J Pharmacol; 2009 Sep; 158(1):225-31. PubMed ID: 19594755
[TBL] [Abstract][Full Text] [Related]
38. Opiorphin causes a panicolytic-like effect in rat panic models mediated by μ-opioid receptors in the dorsal periaqueductal gray.
Maraschin JC; Rangel MP; Bonfim AJ; Kitayama M; Graeff FG; Zangrossi H; Audi EA
Neuropharmacology; 2016 Feb; 101():264-70. PubMed ID: 26363194
[TBL] [Abstract][Full Text] [Related]
39. RGS14 prevents morphine from internalizing Mu-opioid receptors in periaqueductal gray neurons.
Rodríguez-Muñoz M; de la Torre-Madrid E; Gaitán G; Sánchez-Blázquez P; Garzón J
Cell Signal; 2007 Dec; 19(12):2558-71. PubMed ID: 17825524
[TBL] [Abstract][Full Text] [Related]
40. Involvement of prelimbic medial prefrontal cortex in panic-like elaborated defensive behaviour and innate fear-induced antinociception elicited by GABAA receptor blockade in the dorsomedial and ventromedial hypothalamic nuclei: role of the endocannabinoid CB1 receptor.
Freitas RL; Salgado-Rohner CJ; Hallak JE; Crippa JA; Coimbra NC
Int J Neuropsychopharmacol; 2013 Sep; 16(8):1781-98. PubMed ID: 23521775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
